Baseline characteristics
| Characteristic . | Values . |
|---|---|
| Age, y, mean ± SD | 69.1 ± 10.5 |
| Male, n (%) | 13 (65) |
| Clinical history | |
| Hypertension, n (%) | 15 (75) |
| Hypercholesterolemia, n (%) | 17 (85) |
| Diabetes, n (%) | 7 (35) |
| Current smoker, n (%) | 2 (10) |
| Medications | |
| Aspirin, n (%) | 20 (100) |
| Clopidogrel, n (%) | 20 (100) |
| β-blocker, n (%) | 9 (45) |
| ACE-I/ARB, n (%) | 14 (70) |
| Statin, n (%) | 18 (90) |
| Nitrates, n (%) | 7 (35) |
| Characteristic . | Values . |
|---|---|
| Age, y, mean ± SD | 69.1 ± 10.5 |
| Male, n (%) | 13 (65) |
| Clinical history | |
| Hypertension, n (%) | 15 (75) |
| Hypercholesterolemia, n (%) | 17 (85) |
| Diabetes, n (%) | 7 (35) |
| Current smoker, n (%) | 2 (10) |
| Medications | |
| Aspirin, n (%) | 20 (100) |
| Clopidogrel, n (%) | 20 (100) |
| β-blocker, n (%) | 9 (45) |
| ACE-I/ARB, n (%) | 14 (70) |
| Statin, n (%) | 18 (90) |
| Nitrates, n (%) | 7 (35) |
ACE-I indicates angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker.